GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - RHYTHM PHARMACEUTICALS INC

Explicit Guidance:

• 2027 Catalysts: Management does not provide specific financial guidance (revenue, earnings, or margins) for 2027. Instead, they forecast activity milestones: initiation of the Bivromelagon (Vivomelagon) trial for Acquired Hypothalamic Obesity (AHO) "imminently," and initiation of a Prader-Willi syndrome trial mid-year, likely early Q3 2027.
• Data Readouts: Expectation to release 12-month data for the ongoing Prader-Willi study (currently at 6 months) at a medical meeting in early Spring 2027.
• Pricing/Reimbursement Strategy: Plans to seek exceptions to "lifestyle medication" reimbursement rules in Germany for HO, anticipating similar outcomes to prior approvals.

Business-Segment Outlook:

• Acquired Hypothalamic Obesity (AHO):
  • Commercial Traction: Observed steady launch pace into Q4 with 700+ patients starting forms since March 19th; management reports no slowdown and confidence in the "steady nature" of adoption.
  • Market Size: Internal consensus estimates the treatable patient population has grown significantly from the initial 2,000+ (suspected/firmly diagnosed) to 5,000–10,000, driven by deeper penetration and improved identification of suspected cases. Management indicates the number "could be bigger" and plans to update the epidemiology estimate "at the appropriate time" when confidence warrants it.
  • Product Mix: Anticipate developing both daily oral and Rhythm 718 (weekly) formulations for "big opportunities" like HO and Prader-Willi to offer patient choice; smaller indications may rely on a single formulation.
• Prader-Willi Syndrome (PWS):
  • Clinical Expectations: Data shows consistent, though modest, BMI decreases and favorable DEXA scan results (loss of fat > lean mass). The 12-month readout aims to confirm consistency and minimal stabilization in a population destined to gain weight.
  • Market Dynamics: Acknowledges the "noise" in PWS trials due to patient psychology (obsessive-compulsive behaviors, use of food to manage behavior) regardless of satiety signals.
  • Therapeutic Preference: Dr. Miller and the medical team favor the daily oral formulation over weekly for PWS due to the need for routine management of the patient's behavioral profile.
• International Expansion:
  • Europe: Prioritizing Germany for HO launch; acknowledging delays in reimbursement timelines in UK and France.
  • Latin America: Currently "very lightly" penetrated (e.g., one employee in Argentina), with expansion planned as confidence grows.
  • Japan: Recognized for a larger population basis for HO than the US (higher incidence of craniopharyngioma). Launch is expected to be "modest" for the first 12 months due to regulatory "safety drag" requiring two-week prescription fills with in-person physician visits. This restriction is expected to lift after one year, potentially accelerating revenue uptake thereafter.

Market and Competitive Outlook:

• Competitive Positioning: Distinguishes MC4R agonism from GLP-1s by emphasizing a physiologic mechanism (restoring satiety) that preserves lean mass, contrasting with the "starvation state" and lean mass loss associated with GLP-1s.
• Rare Disease Growth Model: Management anticipates rare disease opportunities "grow for decades" rather than following a standard "zero to peak in five years then plateau" trajectory, citing the historical growth of the Genzyme/Gaucher model.
• Market Entry Strategy: Adopts a "pay as you go" model for international markets, investing capital as confidence in unlocking specific countries is established.

Macro / Industry Outlook:

• Reimbursement Landscape: Notes that obesity medications are frequently classified as "lifestyle medications" in Europe, creating regulatory hurdles (e.g., GBA exceptions in Germany) that require specific negotiation.
• Regulatory Environments: Highlights dynamic and variable timelines for reimbursement across European markets (specifically UK/France).
• Economic/Financial Structure: Management emphasizes being "dilution sensitive" and "shareholder friendly," utilizing the $750 million debt facility (drawing $250 million) to fund growth without equity dilution, citing confidence in the path to profitability.

Strategic Initiatives:

• LG Chem Partnership Amendment: Executed a royalty buy-down to remove the "per-indication royalty escalation" (capped previously at 7%), aligning incentives so portfolio decisions are driven solely by science rather than royalty structures. The deal validates consensus estimates for the future value of the portfolio.
• Pipeline Development: Planning to initiate trials for Bivromelagon in AHO and PWS (mid-year/early Q3 2027) and potentially explore combination therapies to amplify MC4R agonism effects in 2027.
• Global Footprint: Building direct commercial capabilities in Japan (50+ staff) and Europe, while utilizing partnerships or cautious expansion in Latin America.

Risks and Headwinds to Outlook:

• Diagnostic Delays: AHO launch velocity is currently gated by the need to move patients from "suspected" to "firmly diagnosed" status within a medical community historically unfamiliar with the diagnosis.
• Regulatory/Clinical Hurdles: In Japan, a 12-month systemic delay in prescribing frequency (2-week limit) will artificially suppress initial revenue velocity.
• Pricing/Reimbursement Uncertainty: Variability in reimbursement timeframes and policies across European countries introduces uncertainty for international rollout.
• Trial Noise: PWS clinical data may suffer from "noise" due to patient behavioral factors (OCD) that persist even if the biological drive is addressed, complicating the demonstration of efficacy.
• Epidemiology Uncertainty: Current patient population estimates (2,000–10,000) are "softer" numbers based on physician interaction and may change as real-world diagnostic data accumulates.

Management Tone on the Future:

• Confidence: High confidence in the biology of the MC4R pathway and the growth potential of the acquired hypothalamic obesity opportunity, described as "consistent" and "profound."
• Strategic Shift: Expresses a clear move toward commercial profitability and debt leverage rather than equity dilution, signaling a transition from pure development to a commercial-scale biopharmaceutical company.
• Cautious Optimism: While bullish on long-term rare disease growth, management advises caution regarding short-term data points (e.g., "two data points in a rare disease") and avoids providing rigid quantitative revenue guidance.

Miscellaneous:

• M&A/Rumors: Explicitly declined to comment on recent media reports and rumors regarding M&A or company strategy, stating a policy of not discussing such matters publicly.
• Product Naming: Clarified the development of both Bivromelagon (daily) and Rhythm 718 (weekly), with the latter being a key component of the LG Chem deal.